Bosentan

CAS 147536-97-8 19 current records 1 historicalSmall Molecule

Who holds supplier records for Bosentan? 19 organisations hold a current record for Bosentan: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (15), France (2), Malta (1) and China (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Bosentan: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/bosentan

Reading the evidence

  • 19 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    15 of the 19 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 11 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Bosentan expires 28 Dec 2027. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (19)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Bosentan. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Bosentan sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Bosentan are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • TAI HENG INDUSTRY CO LTD
    Inactive DMF 25169 · filed Jul 2011

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (11 listed products contain Bosentan). The latest listed patent expires 28 Dec 2027. The latest listed exclusivity ended 14 Feb 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Bosentan is a dual endothelin receptor antagonist that is used in the management of pulmonary arterial hypertension (PAH). It works by blocking the effects of endothelin-1, a substance in the walls of blood vessels that causes them to constrict, therefore improving blood flow and reducing blood pressure.

Chemical identity

IUPAC name
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide;hydrate
Canonical SMILES
CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC.O
InChIKey
SXTRWVVIEPWAKM-UHFFFAOYSA-N
Synonyms
Tracleer API, bosentan hydrate, bosentan monohydrate, ro 47-0203/029, ro-47-0203-029, ro-47-0203/029, ro-470203029, tracleer

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Endothelin Receptor Antagonist
Mechanism of action
Cytochrome P450 2C9 Inducers; Cytochrome P450 3A Inducers; Endothelin Receptor Antagonists

Therapeutic areas

Cardiovascular DiseasesPulmonary HypertensionPulmonary Diseases

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Bosentan?

19 organisations hold an active US FDA Type II Drug Master File or a CEP for Bosentan: Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), Amino Chemicals Ltd (Malta), APITORIA PHARMA PRIVATE LTD (India), Cadila Pharmaceuticals Limited (India), CHEMWERTH INC (France), Cipla Limited (India) and HONOUR LAB LTD (India), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Bosentan Drug Master Files are active?

Alembic Pharmaceuticals Limited (DMF 25099), ALIVUS LIFE SCIENCES LTD (DMF 24124), Amino Chemicals Ltd (DMF 23455), APITORIA PHARMA PRIVATE LTD (DMF 26865), Cadila Pharmaceuticals Limited (DMF 26632), CHEMWERTH INC (DMF 29001), Cipla Limited (DMF 29029) and HONOUR LAB LTD (DMF 36018) and 11 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Bosentan records mean?

1 organisation has only inactive Type II DMFs for Bosentan. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Bosentan?

Yes. The latest patent listed for an approved US product containing Bosentan expires 28 Dec 2027, across 11 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Bosentan supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Bosentan?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.